@article{CJCR4351,
author = {Lian Chen and Rui Chen and Zhe Zhu and Yichen Zhang and Zhengwei Wen and Yun Li and Xiaoming Li and Yuwen Luo and Liyu Ma and Shuguang Lin and Xin Chen},
title = {Predictive factors associated with gefitinib response in patients with advanced non-small-cell lung cancer (NSCLC)},
journal = {Chinese Journal of Cancer Research},
volume = {26},
number = {4},
year = {2014},
keywords = {},
abstract = {Purpose: A number of different clinical characteristics have been reported to singly correlate with therapeutic activity of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in advanced non-small-cell lung cancer (NSCLC). This study aimed to identify predictive factors associated with prognostic benefits of gefitinib.
Patients and methods: EGFR gene typing in 33 advanced NSCLC patients received gefitinib (250 mg/day) were analyzed with mutant-enriched PCR assay. Gefitinib response was evaluated with potential predictive factors retrospectively.
Results: The overall objective response rate (ORR) and median progression-free survival (PFS) in the 33 patients treated by gefitinib were 45.5% and 3.0 (2.0-4.0) months. The ORR and median PFS in EGFR gene mutation patients were significantly higher/longer than those in EGFR gene wild-type patients (P<0.01). Similarly, the ORR and median PFS in non-smoker patients were significantly higher/longer than those in smoker patients (P<0.05, P<0.01, respectively). However, no difference for ORR and median PFS occurred between male and female patients. Logistic multivariate analysis showed that only EGFR mutated gene was significantly associated with the ORR (P<0.01). Both EGFR mutated gene and non-smoker were the major factors that contributed to PFS (P<0.05).
Conclusions: EGFR mutated gene and non-smoker status are potential predictors for gefitinib response in NSCLC patients.},
issn = {1993-0631}, url = {https://cjcr.amegroups.org/article/view/4351}
}